Which peptide for hair growth? GHK-Cu & PTD-DBM

A peptide for hair growth is a research direction, but no peptide has the human evidence needed to replace established hair-loss treatments. GHK-Cu has lab, animal, and combination-treatment data, while PTD-DBM has restored hair growth in preclinical models by reopening Wnt signaling. Both remain early.

Which peptides are actually being studied for hair growth?

GHK-Cu and PTD-DBM are the two clearest research names, but they are not interchangeable. GHK-Cu is a copper-carrying tripeptide used in cosmetic serums. PTD-DBM is an engineered peptide built to interfere with a specific brake on follicle signaling. A long ingredient list is not the same thing as a hair-count trial.

The phrase “peptide for hair growth” can describe a cosmetic ingredient, a laboratory tool, or an experimental drug candidate. A serum may improve scalp feel without reversing follicle miniaturization, while mouse fur does not establish a human treatment. The cosmetic peptide hub maps the wider ingredient family and its different jobs.

Does GHK-Cu grow human hair?

GHK-Cu does not yet have clean human evidence showing that GHK-Cu alone regrows hair on a living scalp. The direct case includes cell biology, mouse work, and human combination treatment. That is enough to justify research, but not enough to know how much hair a GHK-Cu serum adds, who responds, or whether any change lasts.

A 2023 formulation study delivered GHK-Cu through a microemulsion and reported hair-growth effects in mice. The experiment tested both a peptide and a delivery system in animals, so it cannot tell us what an ordinary human scalp serum does (PubMed PMID 38026438).

One frequently blurred citation studied AHK-Cu, not GHK-Cu. AHK-Cu encouraged isolated human hair follicles to elongate at concentrations from 10^-12 to 10^-9 molar (PubMed PMID 17703734). Human tissue is useful, but AHK-Cu differs at its first amino acid and ex-vivo growth is not a clinical result.

A 2025 report delivered copper peptides, minoxidil, and dutasteride together through tattooing. Hair improved, but the design cannot assign the change to copper peptides rather than the drugs or procedure (PubMed PMID 40225275). The result belongs to the package, not GHK-Cu alone.

How does PTD-DBM work?

PTD-DBM is designed to release a molecular brake called CXXC5 from the Wnt/beta-catenin pathway, which helps govern follicle growth and regeneration. “PTD” helps the research peptide enter cells; the Dishevelled-binding motif competes at the CXXC5–Dishevelled contact. The plain-English version: PTD-DBM tries to lift the brake rather than press the growth pedal harder.

The 2017 study found more CXXC5 in miniaturized follicles from human balding scalp and tested the pathway in human dermal papilla cells. Topical competitor peptide accelerated hair regrowth and wound-induced new-follicle formation in mice (Journal of Investigative Dermatology). Human material supports the target; the treatment outcome came from mice.

A later study linked dihydrotestosterone (DHT) and prostaglandin D2 with CXXC5-driven suppression of Wnt signaling. PTD-DBM restored suppressed growth in mouse and follicle models (PubMed PMID 36831222). PTD-DBM therefore has a coherent mechanism, not a human efficacy result.

Which peptide for hair growth has the better evidence?

GHK-Cu has the broader cosmetic history, while PTD-DBM has the sharper hair-follicle mechanism. Neither has a decisive human monotherapy trial for hair regrowth. Choosing a “winner” would reward familiarity on one side or elegant biology on the other, when the outcome people care about—more durable hair on a human scalp—has not been established for either.

Candidate	Best evidence tied to hair	What remains unanswered
GHK-Cu	Mouse delivery study; related AHK-Cu in isolated human follicles; multicomponent human report	Effect of GHK-Cu alone on human hair count, density, and durability
PTD-DBM	Human scalp and cell target work; topical regrowth and follicle-neogenesis results in mice	Human efficacy, tolerability, delivery, and long-term safety

Cell work asks whether a mechanism can operate. Animal work asks whether biology moves in a living system. A controlled human trial asks whether the product helps people. The evidence-grading guide explains why those rungs cannot be swapped because a before-and-after story sounds good.

GHK-Cu vs minoxidil: which actually regrows hair?

Minoxidil is the pick if you want regrowth backed by human trials and an FDA approval; GHK-Cu is a promising cosmetic ingredient without that proof. They are not the same kind of thing. Minoxidil is a topical drug cleared for pattern hair loss with decades of controlled human data behind it (labeled minoxidil products), while GHK-Cu is a copper peptide whose hair evidence stops at cells, mice, and multi-ingredient reports.

That gap decides most practical questions. Minoxidil has a known response rate, a known onset of a few months, and a known catch: stop using it and the gains reverse. GHK-Cu has no established human hair-count trial, no standard dose, and no way yet to say who responds. A serum that feels good on the scalp is not the same as a drug that moved a hair count in a controlled study.

Being peptide-positive does not mean pretending the peptide out-evidences the drug. The reasonable read is complementary, not competitive: minoxidil is the evidence-backed base, and GHK-Cu is a gentler add-on some people layer for scalp condition — not a replacement. The single human report that paired copper peptides with minoxidil and dutasteride can’t separate the peptide’s contribution from the drugs it rode along with. If regrowth is the goal, the evidence points to minoxidil (or finasteride); if you want to try GHK-Cu, treat it as an adjunct while the human data catches up.

Are topical hair peptides safer than injections?

Topical use keeps exposure local, but “topical” does not automatically mean validated or risk-free. GHK-Cu cosmetics can irritate skin, and peptide delivery through the scalp remains a formulation problem. PTD-DBM lacks an established human safety record. Microneedling or tattoo delivery crosses the skin barrier, so it is not equivalent to applying serum.

Injectable GHK-Cu has no established human dose for hair growth or clinical evidence showing that systemic delivery works better. PTD-DBM’s published hair experiments used topical treatment in preclinical models; injection claims run ahead of that record. The peptide side-effects reference separates molecule risks from route, contamination, and sterility risks.

Neither GHK-Cu nor PTD-DBM has an FDA-approved hair-loss indication. DailyMed, by comparison, carries labeled minoxidil hair-regrowth products and finasteride tablets for male pattern hair loss. Approval marks a much higher evidence and manufacturing bar.

How should you judge peptide hair-growth claims?

Judge each peptide for hair growth by five details: exact molecule, species, route, comparison group, and endpoint. “Activated Wnt” is mechanism evidence. Longer isolated follicles are ex-vivo evidence. Mouse fur is animal evidence. A controlled change in human hair count is clinical evidence. Those findings do not belong in one bucket.

Check whether the cited molecule matches the bottle. AHK-Cu data cannot become GHK-Cu data, and “copper peptides” in a mixture cannot establish that GHK-Cu caused the result. Check whether a device drove the formula through skin, then look for controls separating the peptide from other active ingredients.

The honest read is optimistic but narrow. GHK-Cu offers a plausible topical candidate; PTD-DBM offers a precise target linked to follicle regeneration. Human testing must now show meaningful, durable hair beyond a vehicle or established comparator. Until then, reading peptide evidence by endpoint beats ranking serums by how scientific their labels look.